Literatur
- 1
Andersson O K, Neldam S.
The antihypertensive effect and tolerability of candesartan cilexetil, a new generation
angiotensin II antagonist, in comparison with losartan.
Blood Press.
1998;
7
53-59
- 2
Dahlof B, Devereux R B, Kjeldsen S E, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H,
Kristiansson K, Lederballe-Pedersen O, Lindholm L H, Nieminen M S, Omvik P, Oparil S,
Wedel H. The LIFE Study Group .
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint
reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet.
2002;
359
995-1003
- 3 Dominiak P, Heusch G. AT1-Rezeptor-Blockade. 1. Auflage, Steinkopff-Verlag Darmstadt
1999
- 4 Dominiak P, Unger T. Angiotensin II AT1-Rezeptorantagonisten. 2. Auflage, Steinkopff-Verlag
Darmstadt 1999
- 5
Elliott W J, Calhoun D A, DeLucca P T, Gazdick L P, Kerns D E, Zeldin R K.
Losartan versus valsartan in the treatment of patients with mild to moderate essential
hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
Clin Ther.
2001;
23
1166-1179
- 6 Fricke U, Klaus W. Neue Arzneimittel (Hrsg.) Fakten und Bewertungen von 1997 bis
2000 zugelassenen Arzneimittel. Wissenschaftliche Verlagsgesellschaft 2002
- 7
Gradman A H, Lewin A, Bowling B T, Tonkon M, Deedwania P C, Kezer A E, Hardison J D,
Cushing D J, Michelson E L.
Comparative effects of candesartan cilexetil and losartan in patients with systemic
hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group.
Heart Dis.
1999;
1
52-57
- 8
Hedner T, Himmelmann A. The Eprosartan Multinational Study Group .
The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension.
J Hypertens.
1999;
17
129-136
- 9
Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, Sullivan J, Oddou-Stock P.
A comparison of the angiotensin II antagonists valsartan and losartan in the treatment
of essential hypertension.
Am J Hypertens.
1999;
12
414-417
- 10
Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Irbesartan/Losartan Study
Investigators .
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan
in mild-to-moderate hypertension.
Am J Hypertens.
1998;
11
445-453
- 11
Lacourciere Y, Asmar R. Candesartan/Losartan study investigators .
A comparison of the efficacy and duration of action of candesartan cilexetil and
losartan as assessed by clinic and ambulatory blood pressure after a missed dose,
in truly hypertensive patients: a placebo-controlled, forced titration study.
Am J Hypertens.
1999;
12
1181-1187
- 12
Littlejohn T, Mroczek W, Marbury T, Van der Maelen C P, Dubiel R F.
A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan
80 mg in patients with mild to moderate hypertension using ambulatory blood pressure
monitoring.
Can J Cardiol.
2000;
16
1123-1132
- 13
Mallion J, Siche J, Lacourciere Y.
ABPM comparison of the antihypertensive profiles of the selective angiotensin II
receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension.
J Hum Hypertens.
1999;
13
657-664
- 14
Mancia G, Korlipara K, Van Rossum P, Villa G, Silvert B.
An ambulatory blood pressure monitoring study of the comparative antihypertensive
efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
Blood Press Monit.
2002;
7
135-142
- 15
Monterroso V H, Rodriguez C havez V, Carbajal E T, Vogel D R, Aroca M artinez GJ,
Garcia L H, Cuevas J H, Lara T eran J, Hitzenberger G, Leao N eves P, Middlemost S J,
Dumortier T, Bunt A M, Smith R D. Losartan Trial Investigators .
Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy
and safety of two angiotensin II receptor antagonists, losartan and valsartan.
Adv Ther.
2000;
17
117-131
- 16
Oparil S, Guthrie R, Lewin A J, Marbury T, Reilly K, Triscari J, Witcher J A. Irbesartan/Losartan
Study Investigators .
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor
blockers, irbesartan and losartan.
Clin Ther.
1998;
20
398-409
- 17
Oparil S, Williams D, Chrysant S G, Marbury T C, Neutel J.
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control
of essential hypertension.
J Clin Hypertens (Greenwich).
2001;
3
283-291
- 18
Vidt D G, White W B, Ridley E, Rahman M, Harris S, Vendetti J, Michelson E L, Wang R ;.
CLAIM Study Investigators .
A forced titration study of antihypertensive efficacy of candesartan cilexetil in
comparison to losartan: CLAIM Study II.
J Hum Hypertens.
2001;
15
475-480
Prof. Dr. med. Peter Dominiak
Institut für experimentelle und klinische Pharmakologie und Toxikologie, Universitätsklinikum
Schleswig-Holstein, Campus Lübeck
Ratzeburger Allee 160
23538 Lübeck
Phone: 0451/500-2680
Fax: 0451/500-3327
Email: dominiak@medinf.mu-luebeck.de
